06:44 AM EDT, 08/11/2025 (MT Newswires) -- Amphastar Pharmaceuticals ( AMPH ) said Monday the US Food and Drug Administration has approved its abbreviated marketing application for iron sucrose injection in various doses under single-dose vials, previously known as AMP-002.

The company said the injection is used to treat iron deficiency anemia in patients with chronic kidney disease.

"We look forward to launching our iron sucrose injection in the third quarter of 2025," said Dr. Jack Zhang, Amphastar's chief executive officer.

Shares of the company were up 3.4% in Monday's premarket activity.

Price: 24.63, Change: +0.82, Percent Change: +3.44